Advanced Renal Cell Carcinoma Recruiting Phase 2 Trials for Telaglenastat (DB15232)

Also known as: Advanced Renal cell carcinoma

IndicationStatusPhase
DBCOND0032596 (Advanced Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03428217CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaTreatment